US05464T1043
US05464T1043
Axsome Therapeutics, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 638.496.000 | 385.693.000 | 65.5% |
| Cost of Revenue | 47.478.000 | 33.303.000 | 42.6% |
| Gross Profit | 591.018.000 | 352.390.000 | 67.7% |
| 760.253.000 | 604.828.000 | 25.7% | |
| Operating Income | -169.235.000 | -252.438.000 | 33.0% |
| Pretax Income | -183.704.000 | -287.131.000 | 36.0% |
| Net Income Common Stockholders | -183.174.000 | -287.216.000 | 36.2% |
| -- | -- | -- | |
| -- | -- | -- |